Advanz Embarks On Strategic Plan By Buying Two Eisai Brands

 
• By Aidan Fry

By paying just over US$33 million for two Eisai legacy brands, Advanz Pharma is starting to deliver on its strategy to acquire and license a portfolio of niche off-patent medicines.

Money
Advanz Pharma has embarked on its strategy of acquiring niche established products • Source: Shutterstock

More from Deals

More from Business